In short
Clinical trials are investigating Mcla-129 in people with advanced non-small cell lung cancer and other solid tumors. The study is looking at how well it works, how safe it is, and how the body handles it. It also includes combination treatment with chemotherapy and osimertinib.
Key points
- Mcla-129 is being studied in one authorised Phase 1 clinical trial for advanced non-small cell lung cancer and other solid tumors. The study includes Mcla-129 alone and in combination with chemotherapy and osimertinib. Researchers are looking at tumor response, safety, treatment changes, and how the drug moves through the body. They are also measuring progression-free survival, duration of response, and overall survival. The trial plans to enroll 287 people.
Trial overview
The available study of Mcla-129 is an interventional clinical trial, which means researchers give a treatment and then measure the results. The trial is titled “Phase 1 / 2 Study Evaluating MCLA-129 in Advanced NSCLC,” and the record provided shows it as a Phase 1 study.
This trial is authorised and plans to enroll 287 participants. The condition listed in the record is solid tumors, and the brief summary shows a focus on advanced non-small cell lung cancer, often shortened to NSCLC.
Who is being studied
The trial is aimed at people with advanced NSCLC and other solid tumors. “Advanced” means the cancer is at a later stage and may be more difficult to treat.
The source data do not list the full inclusion and exclusion rules, so the exact participation rules are not shown in the record provided. This means the study population can only be described from the trial summary available here.
Treatments being tested
The trial is studying single-agent Mcla-129, which means Mcla-129 is used by itself in part of the research. It is also being studied in combination with chemotherapy and osimertinib.
The trial record lists the following study drugs: docetaxel, paclitaxel, carboplatin, osimertinib, and Mcla-129. The record does not explain which exact combination each participant receives, but it clearly shows that researchers are comparing Mcla-129 alone and with other cancer treatments.
What researchers measure
The main tumor result being measured is Objective Response Rate (ORR), which shows how many tumors shrink or disappear during treatment. This is one of the most common ways to see early signs that a cancer treatment may work.
Researchers are also tracking safety and tolerability, including the frequency and severity of adverse events, serious adverse events, treatment discontinuations, and treatment modifications. In simple terms, this tells the team how well people can stay on the treatment and whether side effects lead to stopping or changing it.
Another important area is pharmacokinetics, which describes how the body handles the treatment over time. The record lists measures such as CEOI, Cmax, C0h, AUC, CL, Vss, tmax, t1/2, and population pharmacokinetics. These are technical measures that help researchers understand drug levels, exposure, and how quickly the treatment moves through the body.
The trial also measures Progression-Free Survival (PFS), Duration of Response (DOR), and Overall Survival (OS). PFS shows how long the cancer stays from getting worse, DOR shows how long a response lasts, and OS shows how long people live after starting treatment.
Trial phase and status
The study is listed as Phase 1 in the source data. Phase 1 trials usually focus on safety first, while also looking for early signs of benefit.
The status is Authorised, which means the trial has been approved to move forward in the listed setting. The record does not provide a completion date or final results, so the current outcome of the study is not known from the source material.
What this means for patients
This trial is part of early cancer research for people with advanced NSCLC and other solid tumors. It is designed to answer practical questions: does the treatment shrink tumors, is it safe enough to continue, and how does the body process it?
Because the study includes both Mcla-129 alone and Mcla-129 with other cancer medicines, the researchers are trying to learn whether the treatment may work differently in combination settings. The available record gives a clear early-stage research picture, but not detailed eligibility rules or final study results.